Compare Open Text Corporation (OTEX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs Sana Biotechnology Inc — how do they compare? Open Text Corporation trades at $22.6 (market cap $5.64B), while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: Open Text Corporation is far larger — about 5.5× Sana Biotechnology Inc's market cap, and Open Text Corporation pays a 4.8% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| OTEX | SANA | |
|---|---|---|
Market Cap | $5.64B | $1.03B |
Sector | Technology | Health |
52-Week High | $39.69 | $5.92 |
52-Week Low | $20.01 | $2.68 |
Enterprise Value | $10.66B | $946.04M |
Dividend Yield | 4.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Open Text Corp (OTEX) trades at $23.36, down 2.46% on the day, with a bearish technical signal but attractive valuation multiples (P/E 9.05, P/S 1.11). Recent earnings beats (Q4 2025, Q1 2026, Q2 2026) and a 4.7% dividend yield highlight fundamental strength. The company announced a $105 million investment in European AI and cloud expansion (PRNewsWire, 2026-06-12), signaling growth initiatives amid mixed institutional positioning.
Outlook: Undervalued with strong cash flow and earnings momentum, but near-term technical pressure and high debt ($6.34B) pose risks. Analyst consensus target of $29.33 suggests 25% upside, supported by cloud revenue growth. Key risks include execution on AI investments and competitive software market dynamics.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
